Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
69.03
+0.65 (0.95%)
May 29, 2026, 2:50 PM EDT - Market open
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $164.90M in the quarter ending March 31, 2026, with 4.89% growth. This brings the company's revenue in the last twelve months to $769.10M, up 12.20% year-over-year. In the year 2025, Corcept Therapeutics had annual revenue of $761.41M with 12.79% growth.
Revenue (ttm)
$769.10M
Revenue Growth
+12.20%
P/S Ratio
9.54
Revenue / Employee
$1,053,556
Employees
730
Market Cap
7.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 761.41M | 86.37M | 12.79% |
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Bio-Techne | 1.21B |
| Rhythm Pharmaceuticals | 217.17M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
CORT News
- 1 day ago - Corcept Therapeutics price target raised to $135 from $110 at Canaccord - TheFly
- 1 day ago - Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright - TheFly
- 2 days ago - Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant - TheFly
- 2 days ago - Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome - Business Wire
- 16 days ago - Corcept Therapeutics upgraded to Buy from Neutral at UBS - TheFly
- 16 days ago - Corcept Therapeutics upgraded to Buy from Neutral at UBS - TheFly
- 25 days ago - Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright - TheFly
- 4 weeks ago - Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler - TheFly